TITLE

FDA/EMA ROUNDUP

PUB. DATE
March 2013
SOURCE
MondayMorning;3/18/2013, Vol. 21 Issue 10, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses news briefs related to pharmaceutical industry. Approval of an imaging drug for locating lymph nodes in breast cancer and skin cancer patients is won by Navidea Biopharmaceuticals Inc. Various diabetes drugs are being scrutinized by the U.S. for their potential risk of pancreatic cancer. The U.S. Food and Drug Administration (FDA) is planning to loose the rules related to approval of Alzheimer's disease treatment.
ACCESSION #
86435108

 

Related Articles

  • FDA/EMA ROUNDUP.  // MondayMorning;9/17/2012, p1 

    The article offers news briefs related to the pharmaceutical industry in the U.S. as of September 17, 2012. Sanofi SA was granted approval by the Food and Drug Administration (FDA) to market its multiple sclerosis drug in the country. Navidea Biopharmaceuticals Inc.'s drug approval application...

  • First drug approved for severe Alzheimer's. LoBuono, Charlotte // Drug Topics;11/17/2003, Vol. 147 Issue 22, p24 

    Reports on the U.S. Food and Drug Administration's approval of memantine for the treatment of moderate to severe Alzheimer's disease. Inhibition of excitotoxic effect by binding preferentially to N-methyl-D-aspartate receptors and blocking cation channels; Common adverse effects;...

  • Lupin wins FDA tentative approval for Alzheimer's drug.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p7 

    No abstract available.

  • Higher Dosage Of Aricept OK'd.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p33 

    The article reports on the approval of Aricept, a dopaminergic for the treatment of Alzheimer's diseases, comarketed by Eisai Inc. and Pfizer Inc., by the U.S. Food and Drug Administration (FDA).

  • Navidea Biopharmaceuticals Announces $50 Mln Credit Facility with Platinum- Montaur Life Sciences.  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article informs that Platinum-Montaur Life Sciences LLC will provide Navidea Biopharmaceuticals Inc. a credit facility of up to 50 million U.S. dollars. It also informs that this transaction will provide the company financial resources to fund its development and growth plans. It also...

  • WEEK IN REVIEW.  // BioWorld Insight;6/11/2012, Vol. 20 Issue 24, p5 

    The article offers news brief related to biopharmaceutical industry as of June, 2012. Merck Serono partnered with Dr. Reddy's Laboratories Ltd. to co-develop biosimilar cancer compounds. The U.S. Food and Drug Administration has approved the use of horizant, a drug for postherpetic neuralgia...

  • Other News To Note.  // BioWorld Today;7/15/2013, Vol. 24 Issue 133, p3 

    This section offers news briefs related to the pharmaceutical companies as of July 15, 2013. The U.S. Security and Exchange Commission (SEC) has sent Aveo Pharmaceuticals Inc. a subpoena requesting related communications with the U.S. Food and Drug Administration (FDA) concerning its anti-cancer...

  • WASHINGTON ROUNDUP.  // BioWorld Today;1/15/2014, Vol. 25 Issue 10, p7 

    This section offers Washington ruling on pharmaceuticals news briefs as of January 2014 including a bipartisan bill for Food and Drug Administration (FDA) funding awaiting approval of the House and Senate with an increase of 91 million dollars to 2.55 billion dollars as compared to 2013 funding.

  • PHARMACY CORNER.  // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p148 

    This section offers news briefs on the pharmaceutical industry in the U.S. as of January 2007. The Food and Drug Administration (FDA) approved a drug called Zolinda for the treatment of cutaneous T-cell lymphoma (CTCL). Junuvia from Merck & Co. Inc. has been approved by the FDA for the treatment...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics